Gufic BioSciences Ltd
NSE: GUFICBIO BSE: 509079
₹283.05
(0.37%)
Tue, 10 Mar 2026, 11:07 am
Market Cap28.24B
PE Ratio56.73
Dividend0.04
Health Technology
Pharmaceuticals: Major
24.5KGufic BioSciences Analysis
dividend
- Gufic Biosciences is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
- No need to calculate the sustainability of Gufic Biosciences's dividends as it is not paying a notable one for India.
- Gufic Biosciences is not paying a notable dividend for India, therefore no need to check if the payments are stable.
- Gufic Biosciences's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Gufic Biosciences's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- Gufic Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Gufic Biosciences is profitable, therefore cash runway is not a concern.
- Gufic Biosciences is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (24.3%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 2.3x debt.
- Gufic Biosciences's cash and other short term assets cover its long term commitments.
- Interest payments on debt are well covered by earnings (EBIT is 3.3x coverage).
- The level of debt compared to net worth has increased over the past 5 years (107.4% vs 123.7% today).
- Gufic Biosciences's level of debt (123.7%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Gufic Biosciences board of directors is about average.
- Pranav's remuneration is lower than average for companies of similar size in India.
- Pranav's compensation has been consistent with company performance over the past year, both up more than 20%.
misc
- Gufic Biosciences is not covered by any analysts.
- Gufic Biosciences has significant price volatility in the past 3 months.
past
- Gufic Biosciences's 1-year earnings growth exceeds its 5-year average (48.7% vs 33.5%)
- Gufic Biosciences has delivered over 20% year on year earnings growth in the past 5 years.
- Gufic Biosciences used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Gufic Biosciences's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (48.7% vs 22.7%).
- Gufic Biosciences's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Whilst Gufic Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%), this is metric is skewed due to its high level of debt.
value
- 509079 outperformed the Market in India which returned -14.5% over the past year.
- BSE:509079 is up 16.2% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:509079 is up 16.2% outperforming the market in India which returned 8% over the past month.
- Gufic Biosciences's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Gufic Biosciences's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Gufic Biosciences is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Gufic Biosciences is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Gufic Biosciences is overvalued based on earnings compared to the India market.
- 509079 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800